Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Interest Coverage Ratio came in at 23.39 in Q1 2026, down 22.8% year-on-year from 30.3 in Q1 2025, and down 75.05% quarter-over-quarter from 93.75 in Q4 2025.
Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Interest Coverage Ratio across 18 years of filings, most recently posting 23.39 for Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 23.39, down 22.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 38.6 (up 45.78% YoY), and the FY2025 annual result was 41.12, up 47.72% from the prior year.
- Interest Coverage Ratio came in at 23.39 for Q1 2026 at Johnson & Johnson, down from 93.75 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 435.2 in Q2 2022 to a low of 21.58 in Q2 2025.
- The 5-year median for Interest Coverage Ratio is 29.9 (2023), against an average of 72.04.
- Across the five-year window, Interest Coverage Ratio jumped 315.73% in 2022 and tumbled 93.8% in 2023, its largest moves.
- Johnson & Johnson's Interest Coverage Ratio stood at 103.9 in 2022, then grew by 20.17% to 124.85 in 2023, then plunged by 78.96% to 26.27 in 2024, then surged by 256.88% to 93.75 in 2025, then tumbled by 75.05% to 23.39 in 2026.
- The last three Interest Coverage Ratio figures came in at 23.39 (Q1 2026), 93.75 (Q4 2025), and 28.71 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | - |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | - |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.02 Bn | 107.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 23.39 |
| Dec 28, 2025 | 93.75 |
| Sep 28, 2025 | 28.71 |
| Jun 29, 2025 | 21.58 |
| Mar 30, 2025 | 30.30 |
| Dec 29, 2024 | 26.27 |
| Sep 29, 2024 | 26.10 |
| Jun 30, 2024 | 23.96 |
| Mar 31, 2024 | 38.12 |
| Dec 31, 2023 | 124.85 |
| Oct 1, 2023 | 29.90 |
| Jul 2, 2023 | 26.79 |
| Apr 2, 2023 | 26.96 |
| Jan 1, 2023 | 62.80 |
| Oct 2, 2022 | 103.90 |
| Jul 3, 2022 | 102.08 |
| Apr 3, 2022 | 435.20 |
| Oct 3, 2021 | 330.30 |
| Jul 4, 2021 | 155.05 |
| Apr 4, 2021 | 104.68 |